Synairgen (SNG) Share Price, News & Analysis

Company Overview

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

Key Stats

• Today's Range: N/A
• 50-Day Range: 0.80 to 2.19
• 52-Week Range: N/A
• Volume: 2.85 million shs
• Average Volume: 1.63 million shs
• Market Capitalization: £9.04 million
• P/E Ratio: N/A
• Dividend Yield: 1.53%
• Price Target: N/A
• Consensus Rating: N/A

SNG Stock Analysis - Frequently Asked Questions

How were Synairgen's earnings last quarter?

Synairgen plc (LON:SNG) issued its earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share (EPS) for the quarter.

How do I buy shares of Synairgen?

Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Synairgen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca (AZN), Alibaba Group (BABA), boohoo group (BOO), Barclays (BARC), VanEck Gold Miners ETF (GDX) and Legal & General Group (LGEN).

Company Calendar

• Last Earnings: 9/29/2020
• Today: 5/12/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:SNG
• CIK: N/A
• Web: www.synairgen.com
• Phone: +44-23-80512800
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-15,860,268.04
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -29.40%
• Return on Assets: -30.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.76
• Quick Ratio: 6.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: 1.90
• Book Value: GBX 4.75 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 977,714,692
• Free Float: N/A
• Market Cap: £9.04 million
• Optionable: Not Optionable
• Beta: -2.23